A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function

Chemistry and Biology

Volumn 11, Issue 10, 2004, Pages 1455-1463

  Shim, Joong Sup ^a   Lee, Jiyong ^a   Park, Hyun Ju ^b   Park, So Jung ^b   Kwon, Ho Jeong ^a  

^a Sejong University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; PROTEIN KINASE (CALCIUM,CALMODULIN);

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BINDING SITE; CATTLE; CELL CYCLE; CHEMISTRY; COLON TUMOR; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; TUMOR CELL LINE; VALIDATION STUDY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CATTLE; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; CURCUMIN; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 5444253443     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.08.015     Document Type: Article

References (46)

1. Schreiber S.L. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 6:1998;1127-1152
2. Harding M.W., Galat A., Uehling D.E., Schreiber S.L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 341:1989;758-760
3. Sche P.P., McKenzie K.M., White J.D., Austin D.J. Display cloning. functional identification of natural product receptors using cDNA-phage display Chem. Biol. 6:1999;707-716
4. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:1994;756-758
5. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 272:1996;408-411
6. Sharma S.V., Agatsuma T., Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene. 16:1998;2639-2645
7. Sin N., Meng L., Wang M.Q., Wen J.J., Bornmann W.G., Crews C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA. 94:1997;6099-6103
8. Rodi D.J., Janes R.W., Sanganee H.J., Holton R.A., Wallace B.A., Makowski L. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J. Mol. Biol. 285:1999;197-203
9. Shim J.S., Kim D.H., Jung H.J., Kim J.H., Lim D., Lee S.K., Kim K.W., Ahn J.W., Yoo J.S., Rho J.R., et al. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg. Med. Chem. 10:2002;2987-2992
10. Shim J.S., Kim J.H., Cho H.Y., Yum Y.N., Kim S.H., Park H.J., Shim B.S., Choi S.H., Kwon H.J. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem. Biol. 10:2003;695-704
11. Burdine L., Kodadek T. Target identification in chemical genetics. the (often) missing link Chem. Biol. 11:2004;593-597
12. Cheung W.Y. Calmodulin plays a pivotal role in cellular regulation. Science. 207:1980;19-27
13. Veigl M.L., Vanaman T.C., Sedwick W.D. Calcium and calmodulin in cell growth and transformation. Biochim. Biophys. Acta. 738:1984;21-48
14. 2+/calmodulin-dependent protein kinase II in NIH 3T3 cells. J. Biochem. Mol. Biol. 34:2001;212-218
15. Walsh M.P., Vallet B., Autric F., Demaille J.G. Purification and characterization of bovine cardiac calmodulin-dependent myosin light chain kinase. J. Biol. Chem. 254:1979;12136-12144
16. Colbran R.J., Soderling T.R. Calcium/calmodulin-dependent protein kinase II. Curr. Top. Cell. Regul. 31:1990;181-221
17. Rybalkin S.D., Bornfeldt K.E. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb. Haemost. 82:1999;424-434
18. Klee C.B. Concerted regulation of protein phosphorylation and dephosphorylation by calmodulin. Neurochem. Res. 16:1991;1059-1065
19. 2+/calmodulin-regulated nitric oxide synthases. Cell Calcium. 13:1992;427-434
20. Wei J.W., Morris H.P., Hickie R.A. Positive correlation between calmodulin content and hepatoma growth rates. Cancer Res. 42:1982;2571-2574
21. Schuller H.M., Correa E., Orloff M., Reznik G.K. Successful chemotherapy of experimental neuroendocrine lung tumors in hamsters with an antagonist of Ca2+/calmodulin. Cancer Res. 50:1990;1645-1649
22. Schuller H.M., Orloff M., Reznik G.K. Antiproliferative effects of the Ca2+/calmodulin antagonist B859-35 and the Ca(2+)-channel blocker verapamil on human lung cancer cell lines. Carcinogenesis. 12:1991;2301-2303
23. Strobl J.S., Peterson V.A. Tamoxifen-resistant human breast cancer cell growth. inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13 J. Pharmacol. Exp. Ther. 263:1992;186-193
24. Hait W.N., Lazo J.S. Calmodulin. a potential target for cancer chemotherapeutic agents J. Clin. Oncol. 4:1986;994-1012
25. Hait W.N. Targeting calmodulin for the development of novel cancer chemotherapeutic agents. Anticancer Drug Des. 2:1987;139-149
26. Nakayama S., Kretsinger R.H. Evolution of the EF-hand family of proteins. Annu. Rev. Biophys. Biomol. Struct. 23:1994;473-507
27. Ikura M., Clore G.M., Gronenborn A.M., Zhu G., Klee C.B., Bax A. Solution structure of a calmodulin-target peptide complex by multidimensional NMR. Science. 256:1992;632-638
28. Babu Y.S., Sack J.S., Greenhough T.J., Bugg C.E., Means A.R., Cook W.J. Three-dimensional structure of calmodulin. Nature. 315:1985;37-40
29. Vandonselaar M., Hickie R.A., Quail J.W., Delbaere L.T. Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat. Struct. Biol. 1:1994;795-801
30. Osawa M., Swindells M.B., Tanikawa J., Tanaka T., Mase T., Furuya T., Ikura M. Solution structure of calmodulin-W-7 complex. the basis of diversity in molecular recognition J. Mol. Biol. 276:1998;165-176
31. Shiotsu Y., Neckers L.M., Wortman I., An W.G., Schulte T.W., Soga S., Murakata C., Tamaoki T., Akinaga S. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood. 96:2000;2284-2291
32. Bosch M., Gil J., Bachs O., Agell N. Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1). J. Biol. Chem. 273:1998;22145-22150
33. Villalonga P., Lopez-Alcala C., Bosch M., Chiloeches A., Rocamora N., Gil J., Marais R., Marshall C.J., Bachs O., Agell N. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell. Biol. 21:2001;7345-7354
34. Shin S.Y., Kim S.Y., Kim J.H., Min D.S., Ko J., Kang U.G., Kim Y.S., Kwon T.K., Han M.Y., Kim Y.H., et al. Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells. J. Biol. Chem. 276:2001;7797-7805
35. Agell N., Bachs O., Rocamora N., Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell. Signal. 14:2002;649-654
36. Zhang M., Tanaka T., Ikura M. Calcium-induced conformational transition revealed by the solution structure of apo calmodulin. Nat. Struct. Biol. 2:1995;758-767
37. Kuboniwa H., Tjandra N., Grzesiek S., Ren H., Klee C.B., Bax A. Solution structure of calcium-free calmodulin. Nat. Struct. Biol. 2:1995;768-776
38. Jackson A.E., Puett D. Binding of trifluoperazine and fluorene-containing compounds to calmodulin and adducts. Biochem. Pharmacol. 35:1986;4395-4400
39. Massom L., Lee H., Jarrett H.W. Trifluoperazine binding to porcine brain calmodulin and skeletal muscle troponin C. Biochemistry. 29:1990;671-681
40. Hidaka H., Yamaki T., Naka M., Tanaka T., Hayashi H., Kobayashi R. Calcium-regulated modulator protein interacting agents inhibit smooth muscle calcium-stimulated protein kinase and ATPase. Mol. Pharmacol. 17:1980;66-72
41. ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell. 73:1993;611-620
42. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:1997;180-186
43. Pumiglia K.M., Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA. 94:1997;448-452
44. Sewing A., Wiseman B., Lloyd A.C., Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17:1997;5588-5597
45. Neckers L., Ivy S.P. Heat shock protein 90. Curr. Opin. Oncol. 15:2003;419-424
46. Chae S.W., Sohn J.H., Shin H.S., Park Y.E. Expression of cyclooxygenase-2 protein in gastric carcinogenesis. Cancer Res. Treat. 34:2002;252-257